Blocking CXCL12 activity through small molecules inhibits CXCR4 completely, which inhibits platelet aggregation and arterial thrombosis, yet leads to leukocytosis whereas using biased or partial antagonists affect signaling differentially to preserve homeostatic functions and do not result in leukocytosis. Here, CXCL12 is linked to Increased total leukocyte count.